Spyre Therapeutics (SYRE) Stock Gains as Guggenheim Elevates It to Top Biotech Position

Key Takeaways

• Guggenheim designated Spyre Therapeutics as its leading biotech selection following encouraging Phase II results for SPY003 in ulcerative colitis treatment
• The SKYLINE-UC trial demonstrated SPY003 achieved 20% clinical remission and 30% endoscopic remission rates
• Baird maintained its Outperform stance with a $116 price objective; Guggenheim maintains a $130 target
• SYRE shares have surged 442% since the beginning of the year, currently hovering near $90.79
• Critical findings from the expanded SKYLINE Part B combination therapy study are anticipated in 2027

Spyre Therapeutics (SYRE) shares climbed more than 2% during Wednesday’s trading session, reaching approximately $90.79, following Guggenheim’s announcement designating the company as its premier biotech selection after reviewing Phase II clinical trial outcomes for SPY003, its ulcerative colitis drug candidate.

Spyre Therapeutics, Inc., SYRE

The clinical study, designated as SKYLINE-UC, assessed SPY003 as a single-agent therapy across three different arms enrolling a total of 135 participants. SPY003 represents an extended-duration anti-IL-23 monoclonal antibody therapeutic.

The findings demonstrated a 20% clinical remission rate, 30% endoscopic remission rate, and a negative 10.0 shift in the Robarts Histopathology Index. According to Guggenheim, these outcomes align with existing IL-23p19 comparator medications currently available on the market.

Approximately 41% of trial participants were classified as advanced therapy-experienced, indicating a substantial portion had previously attempted and failed alternative treatments, including JAK inhibitors and IL-12/23 therapeutic options. The safety assessment returned favorable results, showing zero drug-related serious adverse events and no participant discontinuations attributed to adverse reactions.

Guggenheim emphasized durability as SPY003’s primary competitive advantage, framing it as a promising candidate for combination therapy applications beyond monotherapy use alone.

Analyst Perspectives

Baird reaffirmed its Outperform designation on Wednesday, maintaining its $116 price objective unchanged. The investment firm characterized the SPY003 outcomes as unsurprising given the well-documented mechanism of action, while describing them as incrementally favorable.

Baird noted that the IL-23 inhibitory pathway has already received validation through other authorized medications. The firm’s attention now shifts toward upcoming developments: the expanded, placebo-controlled SKYLINE Part B investigation.

Guggenheim reaffirmed its Buy recommendation with a $130 price objective. Stifel similarly maintained its Buy stance with a $123 target. Mizuho increased its price projection to $120, referencing SPY120’s potential to deliver robust clinical remission outcomes.

However, sentiment isn’t universally optimistic. Wolfe Research downgraded SYRE to Peerperform from Outperform, expressing reservations regarding recent data interpretation and diminished confidence in forthcoming catalysts.

Future Developments

The successful completion of Phase II Part A establishes the foundation for Part B, which is currently enrolling participants. This investigation will examine two dosage levels for each monotherapy alongside three high-dose combination therapy arms, simultaneously targeting the α4β7, TL1A, and IL-23 pathways.

Headline induction results from Part B are projected for release in 2027. Baird indicated this timeframe will deliver the most crucial data supporting the company’s fundamental investment thesis.

A near-term milestone also warrants attention. Spyre’s SPY072 SKYWAY-RD results in psoriatic arthritis and axial spondyloarthritis are scheduled for disclosure in Q4 2026.

Regarding setbacks, Spyre recently disclosed that SPY072 in a rheumatoid arthritis sub-investigation failed to achieve its internal benchmark for monotherapy advancement, despite demonstrating statistically meaningful improvements compared to placebo. This outcome contributed to Wolfe Research’s downgrade decision.

The Wall Street consensus maintains a strong buy recommendation, with price objectives spanning from $97 to $130. SYRE shares have appreciated 442% year-to-date.